Abstract
Background: Recently, there is a new therapy which provides humidified high flow oxygen via nasal cannula (HFNC) has been introduced as an alternative for the treatment of spontaneously ventilating patients with high oxygen requirements.
Objective: to evaluate the efficacy of nasal optiflow device in management of COPD patients in acute exacerbations.
Methods: 45 COPD patients with respiratory failure type II admitted to RICU at Abbasia chest hospital were recruited in two groups:
Group 1: included twenty randomly selected COPD patients in acute exacerbations connected to Venturi-mask,
Group 2: included twenty-five randomly selected COPD patients in acute exacerbations connected to nasal high flow oxygen with optiflow system. All the patients were subjected to full history taking, thorough clinical examination and routine lab investigations with CXR and repeated ABGs.
Results: There was statistically significant improvement in arterial blood gases (ABG) variables (as following: raised PH, PO2 and O2 saturation while PCO2 was declined) when compared to baseline ABG Although there was no significant difference in weaning results between both groups, there was significant decline in PCO2 within NHF group.There was no significant difference in the outcome and the end result between both groups; successful weaning was carried out in 70% of venturi group and 64% of nasal high flow group while failure was reported in 30% of the 1st group and 36% in the 2nd group.
Conclusions: Nasal optiflow device is highly cost comparing to Venturi mask although both are approximately equally successfully in treatment COPD patients with respiratory failure type II .
- Copyright ©ERS 2015